7/14/2023 0 Comments Tyme stock newsThe stock is still down more than 50% year-to-date, although the boost helped it move in the right direction. Summary TYME US90238J1034 TYME TECHNOLOGIES, INC. The stock had closed at around $1.22 per share by day’s end on Wednesday, which is the price it opened at today–the stock market was not open yesterday in observation of Independence Day. : TYME Stock Price US90238J1034 MarketScreener Homepage Equities United States Nasdaq Tyme Technologies, Inc. News Summary TYME US90238J1034 TYME TECHNOLOGIES, INC. TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. : Stock Market News and Information TYME US90238J1034 MarketScreener Homepage Equities United States Nasdaq Tyme Technologies, Inc. “We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients,” he added. Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME ), including its pipeline assets and net cash, after accounting for wind-down and transaction. Tyme Technologies Inc - Company Profile and News - Bloomberg Markets Bloomberg Terminal Demo Request Bloomberg Connecting decision makers to a dynamic network of information, people and ideas. Fears of further bank stress also emerged on reports that PacWest is weighing. Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. “We believe that these outcomes further justify advancing the development of SM-88,” said Chief Medical Officer Giuseppe Del Priore. US stocks dropped Thursday, a day after the Fed delivered a 10th consecutive interest rate hike. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average. biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer. In the meantime, TYME continues to evaluate SM-88 in two, separate Phase II investigator-sponsored studies: one in HR+/HER2- breast cancer and the other in sarcoma.Source: Shutterstock The U.S. While the biotech highlighted Tyson’s industry experience in M&A - indicating it could be one of the options in the cards for the firm - the biotech only added that “there can be no assurance that this process will result in any such transaction, and the company does not intend to disclose additional details unless and until it has entered into a specific transaction.” The biotech said that the board’s strategic planning committee will also act as a transaction committee, lead by former GSK president and TYME board member Tim Tyson. Over the past year shares $TYME are down 80%, with the stock trading at around 35 cents today and a market cap of $60 million - less than cash on hand.īack to today. Our team understood that many efforts before us have failed, but based on SM-88’s prior activity and safety profile, we were hopeful we could provide an effective new option for those fighting against this devastating disease. QuantumScape had operating expenses of 110 million in the first quarter, and it projects that total operating expenses for this year will come in between 225 million and 275 million. ![]() Given pancreatic cancer’s high mortality rate, we wanted to make a difference in the lives of these patients. ![]() The study was testing that combo against different chemo regimens such as gemcitabine.Īt the time the trial was discontinued, TYME CEO Richie Cunningham said in a statement: ![]() This all takes place after a Phase II/III trial was discontinued back in January, when a trial sponsor shut down the study arm due to SM-88, a modified tyrosine derivative plus a regimen known as MPS, being expected to underperform in patients.
0 Comments
Leave a Reply. |